Post by Allen on Jul 29, 2014 21:01:41 GMT -8
Somatostatin Analogues
Lanreotide, Octreotide and Pasireotide (Signifor) are synthetic versions of somatostatin, the hormone responsible for antagonizing somatotropin (growth hormone). As prostate cancer progresses, the somatostatin receptor is less expressed, allowing the cancer to grow more quickly. Somatotropin acts on our bodies through a protein called Insulinlike Growth Factor 1 (IGF1). IGF1 is a potent stimulator of cancer cell growth in its own right, although direct IGF1 inhibitors have so far proved ineffective. It would seem to make a lot of sense to use somatostatin sooner rather than later. It is always given with a corticosteroid.
Here’s a recent review of the use of this class of drugs in oncology:somatostatin-analogues-in-cancer-treatment-....pdf (310.84 KB)
In a Phase 1 pilot study, pasireotide combined with docetaxel and prednisone seemed to delay progression. Hyperglycemia was noted.
Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic castrate-resistant prostate cancer (mCRPC).
Here are some more clinical trial references. (I don't know why all the work on this seems to be happening in Europe.):
• Growth hormone inhibitors in prostate cancer: a systematic analysis.
• Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
• Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement
As an interesting side note, a recent study of over a million people showed an association between height and PC that could not be explained away by other risk factors. Maybe tall guys like me have a surplus of growth hormone:
• Adult height and the risk of cause-specific death and vascular morbidity in 1 million people
Safety
These drugs may have significant effects on heart rate, and may cause hyperglycemia.
Lanreotide, Octreotide and Pasireotide (Signifor) are synthetic versions of somatostatin, the hormone responsible for antagonizing somatotropin (growth hormone). As prostate cancer progresses, the somatostatin receptor is less expressed, allowing the cancer to grow more quickly. Somatotropin acts on our bodies through a protein called Insulinlike Growth Factor 1 (IGF1). IGF1 is a potent stimulator of cancer cell growth in its own right, although direct IGF1 inhibitors have so far proved ineffective. It would seem to make a lot of sense to use somatostatin sooner rather than later. It is always given with a corticosteroid.
Here’s a recent review of the use of this class of drugs in oncology:somatostatin-analogues-in-cancer-treatment-....pdf (310.84 KB)
In a Phase 1 pilot study, pasireotide combined with docetaxel and prednisone seemed to delay progression. Hyperglycemia was noted.
Phase I trial of docetaxel (D), prednisone, and pasireotide (P) (SOM230) in metastatic castrate-resistant prostate cancer (mCRPC).
Here are some more clinical trial references. (I don't know why all the work on this seems to be happening in Europe.):
• Growth hormone inhibitors in prostate cancer: a systematic analysis.
• Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
• Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement
As an interesting side note, a recent study of over a million people showed an association between height and PC that could not be explained away by other risk factors. Maybe tall guys like me have a surplus of growth hormone:
• Adult height and the risk of cause-specific death and vascular morbidity in 1 million people
Safety
These drugs may have significant effects on heart rate, and may cause hyperglycemia.
